title: Flow cytometric analysis of herpes simplex virus type 1 susceptibility to acyclovir, ganciclovir, and foscarnet.
abstract: We established a quantitative flow cytometric method for determination of herpes simplex virus type 1 (HSV-1) susceptibility to acyclovir (ACV), ganciclovir, and foscarnet in vitro. Susceptibility was defined in terms of the drug concentration which reduced the number of cells expressing HSV-1 glycoprotein C (gpC) with a fluorescence intensity of > or =10(2) by 50% (IC50). Flow cytometry allowed us to use a high (1.0) as well as a low (0.005) multiplicity of infection, and determination of the IC50 was possible after one or more viral replicative cycles. IC50s were dependent on virus input and on time postinfection. In mixture experiments, 1 to 2% resistant viruses added to a sensitive strain could be detected. The results obtained by flow cytometry showed a good qualitative correlation with those achieved by cytopathic effect inhibitory assay. However, flow cytometry might detect more quantitative differences in drug susceptibility, especially among resistant strains, as confirmed also by determination of intracellular drug phosphorylation. The mean IC50s for ACV-sensitive strains were 0.45 to 1.47 microM, and those for ACV-resistant strains were between 140 and 3,134 microM. Flow cytometric analysis was fast and accurate, automatizable, and highly reproducible. Flow cytometry may be a more powerful tool than standard cytopathic effect-based assays and could have advantages for the detection of low levels of drug resistance or mixtures of sensitive and resistant virus strains.
authors.affiliation: Abteilung Virologie, Institut für Mikrobiologie, Universität Ulm, Germany.
authors.forename: I
authors.initials: I
authors.lastname: Pavić
authors.forename: A
authors.initials: A
authors.lastname: Hartmann
authors.forename: A
authors.initials: A
authors.lastname: Zimmermann
authors.forename: D
authors.initials: D
authors.lastname: Michel
authors.forename: W
authors.initials: W
authors.lastname: Hampl
authors.forename: I
authors.initials: I
authors.lastname: Schleyer
authors.forename: T
authors.initials: T
authors.lastname: Mertens
mesh_terms: D000212:Acyclovir / Q000378:metabolism / Q000494:pharmacology; D000998:Antiviral Agents / Q000378:metabolism / Q000494:pharmacology*; D005347:Fibroblasts / Q000378:metabolism / Q000821:virology; D005434:Flow Cytometry; D017245:Foscarnet / Q000378:metabolism / Q000494:pharmacology; D015774:Ganciclovir / Q000378:metabolism / Q000494:pharmacology; D006561:Herpes Simplex / Q000378:metabolism; D018259:Herpesvirus 1, Human / Q000187:drug effects*; D006801:Humans; D007700:Kinetics; D008826:Microbial Sensitivity Tests; D010766:Phosphorylation; D014759:Viral Envelope Proteins / Q000096:biosynthesis
chemical_list: D000998:Antiviral Agents; D014759:Viral Envelope Proteins; C038535:glycoprotein gC, herpes simplex virus type 1; D017245:Foscarnet; D015774:Ganciclovir; D000212:Acyclovir